October 23, 2023
The University of Cincinnati Cancer Center's Leeya Pinder joined Local 12's What's Happening in Health to discuss her Cancer Moonshot Scholars research project focused on cervical cancer prevention for women living with HIV in Zambia.
February 29, 2024
Regional media highlighted the University of Cincinnati Cancer Center being the first site in the Midwest enrolling patients in a new Phase 2 clinical trial testing a vaccine to treat pancreatic cancer.
April 17, 2024
Medscape highlighted University of Cincinnati research published in JAMA Dermatology that found skin adverse events were rare following immunotherapy treatments for certain skin cancers.
April 19, 2024
The University of Cincinnati's Leeya Pinder was featured in an Alabama.com/Reckon article about how self-testing for HPV could make preventative care more accessible to those facing the most barriers.
November 7, 2022
MSN India highlighted recent research led by the University of Cincinnati's Trisha Wise-Draper about how immunotherapy and immunosuppression affects COVID-19 severity.
April 14, 2023
Physics World highlighted research led by the University of Cincinnati's Nalinikanth Kotagiri that shows a proof of concept for using engineered bacteria as an adapter to deliver targeted radionuclide treatment to tumors.
May 26, 2023
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Clinical Oncology (ASCO) annual meeting 2023, held in Chicago June 2-6.
October 25, 2021
Dr. Davendra Sohal and Dr. Jordan Kharofa spoke with Angenette Levy of 55KRC on her Simply Medicine program about the risk factors of liver cancer and a new clinical trial scheduled to begin at the UC Cancer Center in January 2022.
May 19, 2023
The University of Cincinnati Cancer Center's Syed Ahmad, MD, is the national principal investigator for a phase 2 trial testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.
September 7, 2022
University of Cincinnati researchers recently published study results in JAMA Otolaryngology showing that administering immunotherapy drug pembrolizumab before surgery for oral cavity cancer did not increase rates of complication during and after surgery.